Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a report released on Monday ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of ...

Leerink downgraded Elevation Oncology (ELEV) to Market Perform from Outperform with a price target of $1, down from $9, after the company ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Shattuck Labs (NasdaqGS:STTK) with a Outperform ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...